Please assess the completion status of the following clinical trial:

Trial Title: Progesterone for Postpartum Cocaine Relapse

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gravidas (women who delivered a baby in the past 12 weeks) who are 18 or older are eligible to participate.~* Women must meet diagnostic criteria for abuse or dependence of cocaine in the six-months prior to conception or during pregnancy.~* Women who abuse other illicit substances or alcohol would also be eligible as long as cocaine was their primary drug of abuse. If women are also opiate dependent, they must be undergoing treatment with methadone or buprenorphine. While we propose to target cocaine we will also monitor the ability of women with polysubstance use to maintain abstinence from substances other than cocaine.~Exclusion Criteria:~Women will be ineligible for the trial if they:~1. have a history of major medical illnesses including liver diseases, suspected or known malignancy, thrombophlebitis, deep vein thrombosis, pulmonary embolus, clotting or bleeding disorders, heart disease, diabetes, history of stroke or other medical conditions that the physician investigator deems as contraindicated for participation in the study;~2. have a known allergy to progesterone or peanuts (vehicle for micronized progesterone);~3. speak a language other than English;~4. are planning on moving out of the area in the first six months after delivery;~5. are unable to understand the study or are unable to provide informed consent;~6. are currently undergoing treatment with another pharmacological agent for substance abuse treatment (with the exception of methadone or buprenorphine as above);~7. have pending incarceration;~8. are currently incarcerated;~9. are using another progestin;~10. are unwilling to accept randomization;~11. are unwilling to use a barrier method of birth control for the duration of the study to ensure that they will not become pregnant.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matched placebo pills to be taken twice daily
- Progesterone (Type: EXPERIMENTAL): 100 mgs progesterone twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).